NewcelX (NCEL) Share-based Compensation (2022 - 2025)

NewcelX (NCEL) posted quarterly Share-based Compensation of $71671.0 for Q2 2025, down 72.7% quarter-over-quarter from $262574.0 in Q2 2023.

NewcelX (NCEL) Share-based Compensation (2022 - 2025) Analysis & Trends

NewcelX (NCEL) has reported Share-based Compensation for 3 consecutive years, with $71671.0 the latest figure, recorded in Q2 2025.

In Q2 2025, Share-based Compensation changed N/A year-over-year to $71671.0; the TTM figure through Jun 2025 stood at $71671.0 (changed N/A YoY), while the FY2025 annual figure was $765000.0, up 267.79% from the prior year.
Share-based Compensation fell to $71671.0 in Q2 2025 per NCEL's latest filing, from $262574.0 in the prior quarter.
Across five years, Share-based Compensation topped out at $306508.0 in Q4 2022 and bottomed at $71671.0 in Q2 2025.
Historically, Share-based Compensation has averaged $213584.3 across 3 years, with a median of $262574.0 in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Stock Comp. (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	108.10 Mn
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn	243.00 Mn
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn	-
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn	120.00 Mn
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn	137.41 Mn
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn	86.63 Mn
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn	28.05 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	41.25 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	NewcelX	12.49 Mn	10.29 Mn	-	-

Download Data